SI1572167T1 - Transdermalni buprenorfinski dozirni reĹľim za analgezijo - Google Patents

Transdermalni buprenorfinski dozirni reĹľim za analgezijo

Info

Publication number
SI1572167T1
SI1572167T1 SI200331365T SI200331365T SI1572167T1 SI 1572167 T1 SI1572167 T1 SI 1572167T1 SI 200331365 T SI200331365 T SI 200331365T SI 200331365 T SI200331365 T SI 200331365T SI 1572167 T1 SI1572167 T1 SI 1572167T1
Authority
SI
Slovenia
Prior art keywords
buprenorphine
dosage form
dosage
analgesia
dosage regimen
Prior art date
Application number
SI200331365T
Other languages
English (en)
Slovenian (sl)
Inventor
Bruce E Reidenberg
Daniel A Spyker
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of SI1572167T1 publication Critical patent/SI1572167T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200331365T 2002-12-13 2003-12-15 Transdermalni buprenorfinski dozirni reĹľim za analgezijo SI1572167T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43342302P 2002-12-13 2002-12-13
EP03813444A EP1572167B1 (en) 2002-12-13 2003-12-15 Transdermal buprenorphine dosage regimen for analgesia
PCT/US2003/039792 WO2004054553A1 (en) 2002-12-13 2003-12-15 Transdermal buprenorphine dosage regimen for analgesia

Publications (1)

Publication Number Publication Date
SI1572167T1 true SI1572167T1 (sl) 2008-12-31

Family

ID=32595187

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200331365T SI1572167T1 (sl) 2002-12-13 2003-12-15 Transdermalni buprenorfinski dozirni reĹľim za analgezijo

Country Status (16)

Country Link
US (1) US7270830B2 (enExample)
EP (1) EP1572167B1 (enExample)
JP (2) JP5054893B2 (enExample)
AT (1) ATE400258T1 (enExample)
AU (2) AU2003297073A1 (enExample)
CA (1) CA2510223C (enExample)
CY (1) CY1108384T1 (enExample)
DE (1) DE60322102D1 (enExample)
DK (1) DK1572167T3 (enExample)
ES (1) ES2310262T3 (enExample)
IL (1) IL169056A (enExample)
MX (1) MXPA05006334A (enExample)
NZ (1) NZ539936A (enExample)
PT (1) PT1572167E (enExample)
SI (1) SI1572167T1 (enExample)
WO (1) WO2004054553A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US7736665B2 (en) * 2002-05-31 2010-06-15 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
MXPA05006334A (es) * 2002-12-13 2005-08-26 Euro Celtique Sa Dosis de buprenorfina transdermica para analgesia.
ATE499100T1 (de) 2003-03-31 2011-03-15 Titan Pharmaceuticals Inc Polymeres implantat zur verzögerten freisetzung von dopamin antagonisten
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
ME00276B (me) * 2003-04-30 2011-05-10 Purdue Pharma Lp Transdermalni dozni oblik otporan na promjene koje sadrže komponentu aktivnog sredstva i komponentu suprotnog sredstva na mjestu koji je ispod sloja aktivnog sredstva
US20080026042A1 (en) * 2003-07-25 2008-01-31 Euro-Celtique S.A. Preoperative Treatment of Post Operative Pain
DK1646328T3 (da) 2003-07-25 2008-02-04 Euro Celtique Sa Behandling af afhængighedsophör
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
EP1968539A2 (en) * 2005-12-13 2008-09-17 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
RU2504377C2 (ru) 2006-07-21 2014-01-20 БайоДеливери Сайенсиз Интэнэшнл, Инк. Способ трансмукозальной доставки лекарства, средство трансмукозальной доставки лекарства (варианты) и способ лечения боли
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
WO2009114118A2 (en) * 2008-03-08 2009-09-17 Theraquest Biosciences, Inc. Oral pharmaceutical compositions of buprenorphine and method of use
US8741930B2 (en) * 2008-10-24 2014-06-03 Bridge Pharma, Inc. Treating xerophthalmia with norketotifen
WO2010059894A1 (en) * 2008-11-21 2010-05-27 Bridge Pharma, Inc. Ocular formulations of norketotifen
SG11201401446RA (en) 2011-08-18 2014-09-26 Biodelivery Sciences Int Inc Abuse-resistant mucoadhesive devices for delivery of buprenorphine
AR089201A1 (es) * 2011-12-12 2014-08-06 Lohmann Therapie Syst Lts Sistema de suministro transdermico
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
AU2013205080B2 (en) * 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
LT2810646T (lt) 2013-06-04 2016-10-25 Lts Lohmann Therapie-Systeme Ag Transderminė tiekimo sistema
WO2017148595A1 (en) * 2016-02-29 2017-09-08 Grünenthal GmbH Titration of cebranopadol
CA3122430A1 (en) * 2018-12-14 2020-06-18 Pear Therapeutics, Inc. A digital therapeutic component to optimize induction of buprenorphine-containing products

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA856002B (en) * 1984-08-10 1987-04-29 Du Pont Transdermal delivery of opioids
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
US5225199A (en) 1990-04-24 1993-07-06 Teijin Limited Pharmaceutical plasters
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
JP2886021B2 (ja) * 1993-03-19 1999-04-26 帝三製薬株式会社 安定な貼付剤
US5613958A (en) 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
JP2837337B2 (ja) * 1993-08-10 1998-12-16 帝三製薬株式会社 貼付剤
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
JP3662388B2 (ja) * 1997-05-30 2005-06-22 日東電工株式会社 経皮吸収製剤及びその製造方法
ES2305457T3 (es) 2002-03-20 2008-11-01 Euro-Celtique S.A. Metodo de administracion de buprenorfina para tratar la depresion.
MXPA05006334A (es) * 2002-12-13 2005-08-26 Euro Celtique Sa Dosis de buprenorfina transdermica para analgesia.
WO2004103317A2 (en) * 2003-05-15 2004-12-02 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for treatment of diarrhea
DK1646328T3 (da) 2003-07-25 2008-02-04 Euro Celtique Sa Behandling af afhængighedsophör

Also Published As

Publication number Publication date
US7270830B2 (en) 2007-09-18
ATE400258T1 (de) 2008-07-15
CA2510223A1 (en) 2004-07-01
DK1572167T3 (da) 2008-10-13
MXPA05006334A (es) 2005-08-26
AU2010201479A1 (en) 2010-05-06
JP5054893B2 (ja) 2012-10-24
AU2003297073A1 (en) 2004-07-09
JP2006513184A (ja) 2006-04-20
NZ539936A (en) 2007-06-29
CA2510223C (en) 2017-09-12
EP1572167A1 (en) 2005-09-14
WO2004054553A1 (en) 2004-07-01
EP1572167A4 (en) 2007-01-10
DE60322102D1 (de) 2008-08-21
PT1572167E (pt) 2008-10-03
JP2010285457A (ja) 2010-12-24
WO2004054553A9 (en) 2005-09-15
AU2010201479B2 (en) 2012-11-01
CY1108384T1 (el) 2014-02-12
US20040126416A1 (en) 2004-07-01
IL169056A (en) 2012-01-31
ES2310262T3 (es) 2009-01-01
EP1572167B1 (en) 2008-07-09

Similar Documents

Publication Publication Date Title
SI1572167T1 (sl) Transdermalni buprenorfinski dozirni reĹľim za analgezijo
EA200300201A1 (ru) Композиция фентанила для интраназального введения
NZ540385A (en) Use of 1-oxo-2-(2, 6-dioxopiperidin-3-yl)-4-methylisoindoline in the manufacture of a medicamnent for treatment of brain cancer
NZ503233A (en) Synergistic analgesic combination of opioid analgesic and COX-2 inhibitor
MY119403A (en) Novel compounds with analgesic effect.
NO20060913L (no) Behandling av avhengighetsabstinens
GB2396108B (en) Treatment of pain
WO2004010946A3 (en) Therapeutic treatment for the metabolic syndrome and type 2 diabetes
WO2001074365A3 (en) An efficacious dosage regimen of galantamine that reduces side effects
NO962655L (no) Deutrerte virkestoffer i transdermal applikasjon
NZ594154A (en) Transdermal administration of buprenorphine for preoperative treatment of post operative pain
NZ590981A (en) Transdermal therapeutic system (TTS) for administration with a wafer
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
AU8900498A (en) Compounds and pharmaceutical compositions thereof for eliciting analgesic effects
EP1347754A4 (en) COMPOSITIONS FOR PREVENTION OF ADHESION
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
DE69814669D1 (de) Pharmaceutische Zusammensetzung enthaltend (+)-EPHEDRIN und einen H1 Rezeptor Antagonisten
UA26886C2 (uk) Солі 1,3-діарил-4,5-поліметилеhімідазолію, що виявляють аhальгезуючу активhість
EA199700025A1 (ru) Применение олигосахарида и аспирина для приготовления медикаментов, предназначенных для лечения тромбоэмболических заболеваний, фармацевтическая композиция, способ лечения
WO2002076405A3 (en) Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
MX9804798A (es) Nuevos compuestos con efecto analgesico.
MX9804797A (es) Nuevos compuestos con efecto analgesico.
UA39418A (uk) Спосіб лікування виразкової хвороби, асоційованої з helicobacter pylori